Novartis AG Is Challenging Biogen On Biogen's Own Turf
Biogen Inc. (NASDAQ:BIIB) may be the Goliath in the $17 billion (and growing) market for multiple sclerosis (MS) treatment, but it's Novartis' (NYSE:NVS) Gilenya, not Biogen's Tecfidera, that's growing more quickly this year.
Some background
MS is a central nervous system disorder caused when the immune system incorrectly damages the protective myelin sheath surrounding nerve fibers, causing nerves to lose their ability to transmit information quickly and efficiently.
Some background
MS is a central nervous system disorder caused when the immune system incorrectly damages the protective myelin sheath surrounding nerve fibers, causing nerves to lose their ability to transmit information quickly and efficiently.